Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03914612
Title Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrial carcinoma

endometrial adenocarcinoma

endometrial serous adenocarcinoma

endometrial mixed adenocarcinoma

endometrial clear cell adenocarcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.